These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28490912)

  • 1. Update on the treatment of narcolepsy: clinical efficacy of pitolisant.
    Calik MW
    Nat Sci Sleep; 2017; 9():127-133. PubMed ID: 28490912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating pitolisant as a narcolepsy treatment option.
    de Biase S; Pellitteri G; Gigli GL; Valente M
    Expert Opin Pharmacother; 2021 Feb; 22(2):155-162. PubMed ID: 32941089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.
    Romigi A; Vitrani G; Lo Giudice T; Centonze D; Franco V
    Drug Des Devel Ther; 2018; 12():2665-2675. PubMed ID: 30214155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
    Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
    Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
    Lamb YN
    CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitolisant for treating patients with narcolepsy.
    Li S; Yang J
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
    Szabo ST; Thorpy MJ; Mayer G; Peever JH; Kilduff TS
    Sleep Med Rev; 2019 Feb; 43():23-36. PubMed ID: 30503715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review.
    Fabara SP; Ortiz JF; Anas Sohail A; Hidalgo J; Altamimi A; Tama B; Patel UK
    Cureus; 2021 Jul; 13(7):e16095. PubMed ID: 34345566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
    Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EFNS guidelines on management of narcolepsy.
    Billiard M; Bassetti C; Dauvilliers Y; Dolenc-Groselj L; Lammers GJ; Mayer G; Pollmächer T; Reading P; Sonka K;
    Eur J Neurol; 2006 Oct; 13(10):1035-48. PubMed ID: 16987156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility.
    Guevarra JT; Hiensch R; Varga AW; Rapoport DM
    Nat Sci Sleep; 2020; 12():709-719. PubMed ID: 33117007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recently Approved and Upcoming Treatments for Narcolepsy.
    Thorpy MJ
    CNS Drugs; 2020 Jan; 34(1):9-27. PubMed ID: 31953791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.
    Watson NF; Davis CW; Zarycranski D; Vaughn B; Dayno JM; Dauvilliers Y; Schwartz JC
    CNS Drugs; 2021 Dec; 35(12):1303-1315. PubMed ID: 34822113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
    Triller A; Pizza F; Lecendreux M; Lieberich L; Rezaei R; Pech de Laclause A; Vandi S; Plazzi G; Kallweit U
    Sleep Med; 2023 Mar; 103():62-68. PubMed ID: 36758348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of narcolepsy with and without cataplexy.
    Kallweit U; Bassetti CL
    Expert Opin Pharmacother; 2017 Jun; 18(8):809-817. PubMed ID: 28443381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.